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Dear Editor, 
It is not unusual for patients with renal insufficien-
cy to develop skin pathologies. There are reports in 
the literature of increased incidence of calciphylaxis, 
pruritus, perforating dermatoses, and porphyria cu-
tanea tarda in this patient population (1). Although it 
is quite rare, Grover’s disease (GD) has been reported 
in several patients with renal insufficiency, but only 
once in a renal transplant recipient (2). The disease 
follows three patterns: persistently pruritic, transient 
eruptive, or a chronic asymptomatic course (3). Com-
mon risk factors concomitant with disease prevalence 
are immunosuppression, HIV, hemodialysis, viral and 
bacterial infections, malignancies, and other skin pa-
thologies like contact and atopic dermatitis (4).
A 60-year-old woman had a family history of 
polycystic kidney disease and was subsequently di-
agnosed in 1997. The patient had concomitant he-
patic involvement and a stable aneurysm of the an-
terior cerebral artery. Consequently, the patient pre-
emptively received a kidney transplant in 2015. The 
immunosuppressive therapy consisted of tacrolimus, 
mycophenolate mofetil, and prednisone with basilix-
imab induction. 
In 2017, a biopsy of the right thigh demonstrated 
squamous cell carcinoma in situ measuring 1×1cm in 
size. The lesion was treated with surgical excision. The 
patient also exhibited an erythematous brown mac-
ule with undefined borders on the left side of the nose 
with a size of 12 mm; it was later determined to be 
actinic keratosis. The lesion was treated successfully 
with cryotherapy. During this period, a fever prompt-
ed a PCR for BK virus DNA which showed a substan-
tial amount of copies, measuring 28,850 copies/mL in 
urine and 98 copies/mL in blood. The mycophenolate 
dose was reduced, and tacrolimus trough concentra-
tion was maintained at between 3 and 5 µg/L. 
In 2018 the patient presented with multiple pru-
ritic erythematous papules located on the trunk. 
Upon histological biopsy, there was dominant supra-
basal acantholysis with numerous cells separating 
from the epithelium. Furthermore, there was a mod-
erate amount of mononuclear infiltrate in the upper 
portion of the dermis and sparse suprabasal clefts 
(Figure 1). Clinical presentation and histologic ex-
amination were consistent with Grover’s disease. The 
patient was treated topically with betamethasone 
cream twice daily for four weeks. The skin changes 
persisted for only a few weeks. 
The pathophysiological mechanism causing GD is 
still unknown. It is usually only a transient skin condi-
tion that lasts no more than a few weeks, but there 
have been more chronic cases lasting for years, par-
ticularly in patients on hemodialysis (5). The lesions 
commonly affect the chest area but may spread to 
diffusely envelope the body as erythematous pap-
ules, pustules, lichenoid lesions, or vesicles (2). Gro-
ver characterized 4 different subtypes based on the 
pathohistological findings as Darier-like (the most 
common), pemphigus vulgaris-like, Hailey-Hailey-
Figure 1. Histopathology of the skin lesion with suprabasal 
acantholysis, numerous cells separating from the epithe-
lium, and a moderate amount of mononuclear infiltrate 
in the upper portion of the dermis and sparse suprabasal 
clefts (hematoxylin and eosin, original magnification ×40).
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like, or spongiotic subtype (3). The histological pat-
terns are not exclusive to one patient and may even 
be found concomitantly in a single lesion. The con-
dition is definitively diagnosed through histology, 
showing distinctive acantholysis along the epidermis 
with dyskeratosis that is described as “corps ronds” 
and “grains” (3).
Grover’s disease is more prevalent in middle-aged 
Caucasian men than any other group, with a 1.6-2.1 
gender ratio (6). It was originally thought that the 
disease was caused by dysfunctional eccrine sweat 
glands, as the ailment was more common in pa-
tients that had increased perspiration either due to 
environmental heat, fever, or extensive bedrest. This 
idea was reinforced by histological evidence of at-
rophied sweat glands in uremic patients with renal 
insufficiency (7). Moreover, a case series and case re-
port described remissions of GD in their patients on 
hemodialysis that received a renal transplant (5,8). 
However, subsequent studies have not supported an 
association with sweat dysfunction and disease de-
velopment, while others have only managed to attri-
bute sweat gland dysfunction as the primary trigger 
in 20-30% of cases (9). Conversely, cold dry air and xe-
rosis cutis is thought to trigger the disease because it 
is four times more likely to be diagnosed in the winter 
months (10). Ultraviolet radiation has been identified 
as an exacerbating factor for GD, which could have 
been the trigger for onset of disease in our patient as 
demonstrated by her squamous cell carcinoma and 
actinic keratosis (11).
Despite immunosuppression being a risk factor for 
GD, as shown by its association in patients with HIV, 
bone marrow transplantation, hemodialysis, and he-
matological malignancies, GD has been reported only 
once in the literature after a renal transplant (2,4). As 
our case, that patient developed GD a few years after 
transplant without an obvious trigger and the lesions 
appeared as red papules that were disseminated over 
the anterior thorax. Their patient’s cutaneous lesion 
resolved spontaneously after 2 weeks and never re-
turned in the 2.5-year follow-up period. Their patient 
has had two renal allografts over a 20 year timespan, 
while ours had had her graft for only two years. The 
immunosuppressive regimen was slightly different: 
cyclosporine, azathioprine, and methylprednisolone 
versus our combination of tacrolimus, mycopheno-
late mofetil, and prednisone. 
Grover’s disease can be treated conservatively by 
avoiding risk factors such as UV light and sweating as 
well as and applying moisturizing emollients which 
may cause the lesion to resolve spontaneously. Medi-
cal therapy consists of topic corticosteroids, topical 
vitamin D analogues, oral retinoids, and oral cortico-
steroids, PUVA, and methotrexate for resistant cases 
(6,12). 
When a patient exhibits pruritic papules of the 
skin, GD should be considered in differential diag-
nosis, especially in kidney transplant patients and 
those on hemodialysis. While the condition is rare, 
increased recognition in this patient population will 
allow for studies to further characterize this poorly 
understood disease.
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